Dr. Andres Felipe Correa, MD

Dr. Correa practices at Fox Chase Cancer Center in Philadelphia, Pennsylvania, part of Thomas Jefferson University.

Dr. Correa's NPI, 1831410588, was assigned on June 17, 2010. Dr. Correa graduated from University of Maryland School of Medicine - Baltimore in 2010. Dr. Correa holds Pennsylvania license MD456743.

Dr. Correa's primary practice is Fox Chase Cancer Center, at 333 Cottman Avenue, Philadelphia, PA 19111.

Dr. Correa's primary practice is Fox Chase Cancer Center in Philadelphia, Pennsylvania, part of Thomas Jefferson University. Dr. Correa is also affiliated with Temple University Hospital. The medical group on file is Temple Faculty Physicians. Dmand AI also links Dr. Correa to 4 more hospitals and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Correa practices, 6 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Correa's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Correa is board certified in urology by the American Board of Urology. Dmand AI has Dr. Correa's licenses on file in 3 states: Pennsylvania, New Jersey and Nebraska.

Dmand AI lists bladder removal, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease and prostate cancer among the conditions Dr. Correa treats.

CMS data shows 1,015 Medicare services from Dr. Correa across 15 procedure codes in 2024, for 371 Medicare patients. Medicare paid $70,638 for them.

CMS counts 371 Medicare patients who saw Dr. Correa in 2024. The largest group is 65 to 74, with 206 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.37, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Correa's median patient age at 73, with 13% women.

In 2024, Dr. Correa wrote 502 Medicare Part D claims for 157 patients. 97% of them were for generic drugs. CMS names the drug for 410 of them, across 10 drugs with 11 or more claims each, at $5,956 in total drug cost. In 2023, CMS named 311 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Correa for performance year 2024, reported as part of a group. Dr. Correa accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 60 papers to Dr. Correa, published from 2012 to 2025. 2023 was the busiest year, with 12. The most frequent topics are Kidney Neoplasms, Carcinoma, Renal Cell and Urinary Bladder Neoplasms. Dr. Correa has published most often in J Urol. Dr. Correa's most frequent co-authors are Robert Guy Uzzo, MD, Laura Bukavina, MD and Marc C. Smaldone, MD.

CMS Open Payments shows 18 general payments to Dr. Correa from 12 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 94% of the total. Boston Scientific Corporation paid the most, $178.

Dr. Correa graduated from University of Maryland School of Medicine - Baltimore in 2010.

Dr. Correa is in network with 18 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.